SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (399)12/20/2003 1:06:25 AM
From: aknahow  Read Replies (1) | Respond to of 824
 
Perhaps sort of picky, but it is clear that Xoma has the choice after seeing Phase II results. If it does not like what it sees it lets the "drug" go back to MLNM and if MLNM brings it to market it gets a royalty. But it is Xoma saying it does not choose to participate in further trials. Of course MLNM may not go further either in which case there will be no royalty payments.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News